3191 results about "Assay" patented technology

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

The present disclosure is drawn to methods of utilizing nucleic acid barcodes and corresponding amplifying sites in cells in which the barcodes naturally occur. These barcodes and amplifying sites are reconfigured into a single nucleic acid cassette that provides for ease of use in tagging particular species, strains, or variants of cells, each with a different barcode. These barcodes can be used to track the colonization capabilities of the barcoded cells. The present disclosure further provides for assays that utilize natural barcodes to measure relative microbial colonization ability of a plant root system.

The invention discloses a monoclonal antibody BY017 combined with African swine fever virus P30 protein and application of the monoclonal antibody BY017. The invention provides an IgG antibody which is composed of a light chain and a heavy chain. CDR1, CDR2 and CDR3 in the heavy chain variable region are sequentially shown as the 47 to 54 , the 72 to 79 and the 118 to 126 in SEQ ID NO: 1; cDR1, CDR2 and CDR3 in a light chain variable region are sequentially as shown in the 49 to 60 , the 78 to 80 and the 117 to 124 in SEQ ID NO: 3. The invention also protects the application of any one of the IgG antibodies in preparation of products. The product has the functions that the product is used for being combined with an African swine fever virus P30 protein fragment; the antibody is used for binding African swine fever virus P30 protein; the antibody is used for binding African swine fever virus. The IgG antibody provided by the invention can be used for multiple purposes of western blot, immunohistochemistry, flow cytometry, ELISA (Enzyme-Linked Immunosorbent Assay) and the like, and can be used as an important tool for ASFV detection and structural analysis of P30 protein of ASFV detection.

A substrate holder includes a base configured to receive a substrate; a cover configured to mateably engage with the base, the cover defining an opening formed by inner sidewalls; and a removable insert defining a surface, the removable insert being configured to be received within the opening of the cover. The removable insert includes a gasket; a projection coupled to the gasket; and at least two insert tabs extending from opposite sides of the removable insert, each insert tab being configured to engage with at least one of the inner sidewalls forming the opening of the cover.

Methods and systems disclosed herein can improve inference of gene expression using cell-free DNA fragments. In an aspect, the present disclosure provides a computer-implemented method for inferring gene expression, the method comprising: obtaining a biological sample from a subject; extracting cell-free deoxyribonucleic acid (cfDNA) from the biological sample, wherein the cfDNA comprises a plurality of cfDNA fragments; performing a sequencing assay on the plurality of cfDNA fragments to generate a plurality of cfDNA sequencing fragments; computer processing the plurality of cfDNA sequencing fragments; and calculating, based at least in part on the computer processing, a gene expression score for a gene in a plurality of genes, wherein the gene expression score indicates a probability of expression or non-expression of the gene in the plurality of genes.

The invention discloses a CKD special disease database construction method and system, and relates to the technical field of database construction, and the method comprises the steps: obtaining and predicating a multi-source heterogeneous atomic fact; constructing and fusing three sets of ontology models; verifying and deducing facts in a layered manner according to a multi-layer priority rule base; calling a constraint completion engine to generate inference facts for missing or conflicting fields; streaming follow-up visit, test and intervention logs into events and triggering graded alarms; an anti-fact intervention scene is simulated for the high-risk patient, and pilot groups are screened; dynamically evaluating and adjusting the rule priority; and based on a causal chain and an event mode, clustering patients and constructing a generality map, and recording a whole-process operation chain. Semantic management is realized through fusion of ontology, anti-fact intervention simulation is performed on high-risk patients by means of multi-layer rule verification, and database semantic consistency, reasoning depth, decision support and traceability are improved through causal atlas driven clustering.

The invention discloses an intelligent coagulant adding method for a waterworks. The method comprises the following steps: acquiring test data and production statistical data of the waterworks in a historical time period; performing data processing on the test data and the production statistical data to obtain a target data set for training; training the initial addition model by using the target data set to obtain a target addition model; obtaining current monitoring data of the water quality of the water plant, and inputting the current monitoring data into the target adding model to obtain a predicted adding amount of the coagulant; on the basis of the factory water turbidity monitored in real time, the feedback regulating quantity of the predicted adding quantity is determined; and performing feedback adjustment on the predicted dosage based on the feedback adjustment quantity to obtain a target dosage corresponding to the current monitoring data, and adding the target dosage to the waterworks. The condition that the outgoing water quality does not reach the standard when the incoming water quality abnormally fluctuates is avoided, and stable water quality control of a water plant is ensured.

The invention provides an influenza A / B virus sandwich method detection reagent. The influenza A / B virus sandwich method detection reagent comprises a pair of influenza A virus antibodies and a pair of influenza B virus antibodies, the pair of influenza A virus antibodies comprises a labeled antibody 19C7 and a coated antibody 27H4, the heavy chain amino acid sequence of the 19C7 antibody is SEQ ID NO: 1, and the light chain amino acid sequence of the 19C7 antibody is SEQ ID NO: 2; the heavy chain amino acid sequence of the 27H4 antibody is SEQ ID NO: 9, and the light chain amino acid sequence of the 27H4 antibody is SEQ ID NO: 10; the pair of influenza B virus antibodies comprises a labeled antibody 10G11 and a coated antibody 23E2, the heavy chain amino acid sequence of the 10G11 antibody is SEQ ID NO: 17, and the light chain amino acid sequence of the 10G11 antibody is SEQ ID NO: 18; the heavy chain amino acid sequence of the 23E2 antibody is SEQ ID NO: 25, and the light chain amino acid sequence of the 23E2 antibody is SEQ ID NO: 26. The sandwich method detection reagent has extremely high specificity and sensitivity.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

The present invention is directed to methods for improving assay specificity and performance in binding assays.

The invention provides a recombined protein rSp14-3-3 of sarcocystis tenella, an antibody and an ELISA (Enzyme-Linked Immunosorbent Assay) diagnostic kit of the recombined protein rSp14-3-3 of the sarcocystis tenella. The research firstly provides the recombined protein rSp14-3-3 of the sarcocystis tenella. According to the present invention, the recombinant protein rSp14-3-3 is used as a gene fragment, the obtained gene fragment is connected to an expression vector to carry out induced expression and protein purification, the purified recombinant protein rSp14-3-3 is used to coat an ELISA plate, the ELISA detection method for sheep infected with sarcosporidium is established, and the specific monoclonal antibody for the recombinant protein rSp14-3-3 is further provided. All the products can be applied to diagnosis of infection of sarcocystis in samples, water samples, food, environmental samples and the like, and technical support is provided for subsequent immunological diagnosis of sheep sarcocystis by using the protein.

Provided are a madecassoside composition with a skin repair effect and use thereof. A scratch experiment demonstrated that madecassoside derivatives I and II have good effects in promoting the closure of the intercellular gaps between human keratinocytes. A subsequent transdermal experiment and an assay of skin repair-related factor expression found that the efficacy can be potentially enhanced by compounding the madecassoside derivatives I and II. Formulations were then screened for optimal acne-removing effects in an efficacy study in humans. Finally, the safety and applicability of the derivatives as cosmetic starting materials were verified in a safety study. The studies on madecassoside derivatives facilitate the application and development of Centella asiatica in acne-removing cosmetics.

The invention belongs to the technical field of pressure sore treatment, and discloses an experimental test method for treating stress injury based on danshen emodin, which comprises the following specific steps: step 1, preparing experimental materials, selecting a healthy SD (Sprague Dawley) rat, and preparing a clean and sterile magnet and a shaver; the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 1 part of isoflurane, 1 part of iodophor, 1 part of Vaseline, 1 part of Rhapontigenin and 1 part of resveratrol. The method comprises the following steps: modeling a stress injury model for an SD (Sprague Dawley) rat so as to simulate a stress injury disease, then respectively smearing three medicines, i.e., Danjie emodin, resveratrol and vaseline, tracking the healing condition of a stress injury wound, and finally performing ELISA (Enzyme-Linked Immunosorbent Assay) and Hamp; according to the present invention, the detection analysis is performed through the dyeing E, and the results show that the rheum emodin has good treatment effect on the stress injury, can reduce the expression of the proinflammatory factor, can promote the wound healing, has characteristics of environmental protection and low cost, and provides the new research direction for the treatment of the stress injury.

Methods and devices for analyzing non-volatile organics in exhaled breath and other aerosols using various diagnostic tools that enable rapid, low-cost point of care assays for several diseases including respiratory tract diseases such as COVID-19. The disclosed methods and systems selectively capture non-volatile organics in exhaled breath and other aerosols in a packed bed column. The non-volatile organics are eluted and samples are analysis using diagnostic devices including MALDI-TOFMS. The disclosed systems and methods provide for a diagnostic test result in less than about 20 minutes and provides for autonomous operation with minimal human intervention.

The invention provides a method for detecting a virus inactivation effect by an ELISA (Enzyme-Linked Immunosorbent Assay) method, which comprises the following steps: acquiring a to-be-detected inactivated virus sample, extracting an antigen component from the sample, and detecting an antigen structure change characteristic value through a high-throughput mass spectrometry analysis technology to obtain antigen degradation degree data; obtaining a sample subjected to preliminary inactivation, and detecting the antigen content change trend through an enzyme-linked immunosorbent assay to obtain content change curve data; detecting the residual quantity of viral nucleic acid by a real-time fluorescent quantitative PCR (Polymerase Chain Reaction) technology aiming at the immunogenicity retained sample to obtain nucleic acid degradation degree data; acquiring nucleic acid degradation degree data, classifying the relationship between nucleic acid residues and infectivity by adopting a support vector machine algorithm, and judging that the inactivation effect is completely completed if the classification result shows that the infectivity is lost; according to the antigen content change trend, the immunogenicity index and the nucleic acid degradation degree data, a weighted fusion algorithm is adopted to integrate multi-dimensional detection results, and a comprehensive inactivation effect score is obtained.

This disclosure provides for devices, methods, and systems for generating a plurality of droplets within a collecting container at an extremely high rate (e.g., of at least 1 million droplets per minute, etc.), each of the plurality of droplets comprising an aqueous mixture for a digital analysis, wherein upon generation, the plurality of droplets is stabilized in position within a region of the collecting container. The inventions enable partitioning of samples for digital analyses at unprecedented rates, where readout of signals from targets within such partitions can still be achieved in accordance with various assays.

Systems and methods for determining a blood tumor mutational burden (bTMB) for a test subject are provided in which there is obtained, from a panel-enriched sequencing reaction, a plurality of nucleic acid sequences. The plurality of nucleic acid sequences comprises a corresponding sequence for each cell-free DNA fragment in a plurality of cell-free DNA fragments obtained from a liquid biopsy sample from the test subject. Each respective cell-free DNA fragment in the plurality of cell-free DNA fragments corresponds to a respective probe sequence in a plurality of probe sequences used to enrich cell-free DNA fragments in the liquid biopsy sample in the panel-enriched sequencing reaction. There is determined, using the panel-enriched sequencing reaction, that a circulating tumor fraction (ctFE) is above a threshold ctFE value. Responsive to this determination, the bTMB is calculated for the test subject from the panel-enriched sequencing reaction and reported.

The present disclosure is drawn to methods of utilizing nucleic acid barcodes and corresponding amplifying sites in cells in which the barcodes naturally occur. These barcodes and amplifying sites are reconfigured into a single nucleic acid cassette that provides for ease of use in tagging particular species, strains, or variants of cells, each with a different barcode. These barcodes can be used to track the colonization capabilities of the barcoded cells. The present disclosure further provides for assays that utilize natural barcodes to measure relative microbial colonization ability of a plant root system.

Providing a fluid to an instrument comprises supporting a sample receptacle on a first carrier, transporting the first carrier on a conveyor adjacent a plurality of modules including at least one instrument, stopping the first carrier at the instrument, transporting the sample receptacle to a pick-up position of the instrument, transporting the sample receptacle from the pick-up position to a pipetting station within the instrument, aspirating fluid within the sample receptacle and transferring the aspirated fluid to a reaction receptacle, after aspirating fluid from the sample receptacle, transporting the sample receptacle to the pick-up position, transporting the sample receptacle from the pick-up position to a second carrier the conveyor, in the instrument, performing an assay to determine the presence or absence of an analyte in the aspirated fluid, and transporting the second carrier on the conveyor to one or more of the plurality of modules other than the analytical instrument.

The invention provides a characteristic protein of serotype I chicken Marek's disease virus and detection application, and belongs to the technical field of virus detection. The invention provides a recombinant gene derived from serum I type chicken Marek's disease virus. The nucleotide sequence of the recombinant gene is shown as SEQ ID No. 1. The recombinant gene disclosed by the invention is used for coding the MDV-1 recombinant PP38 protein, and the MDV-1 recombinant PP38 protein can be applied to enzyme-linked immuno sorbent assay (ELISA) detection. The invention also provides an ELISA detection kit constructed by using the MDV-1 recombinant PP38 protein, and the ELISA detection kit can be used for clinical MDV-1 serum antibody detection, SPF chicken screening, exogenous virus antibody detection of poultry live vaccines or virus seeds, epidemiological investigation and the like, so as to prevent and control transmission of MDV-1 infection.

The invention discloses an enzyme linked immunosorbent assay kit for detecting a plasticizer in edible oil and application of the enzyme linked immunosorbent assay kit, and belongs to the technical field of enzyme linked immunosorbent assay. The enzyme linked immunosorbent assay kit comprises an elisa plate coated with a plasticizer coupling antigen, a plasticizer standard substance, an enzyme conjugate working solution, a plasticizer specific antibody working solution, a purification tube, a purification reagent, a standard substance diluent, a sample diluent, a substrate solution, a stop solution and a 10 * concentrated washing solution. The standard substance diluent provided by the invention is used for diluting a plasticizer standard substance at different temperatures to obtain a plasticizer standard solution, and the obtained plasticizer standard solution has basically consistent inhibition ratio, so that the stability of the kit is remarkably enhanced; meanwhile, the standard diluent and other components in the kit have a synergistic effect, so that the enzyme linked immunosorbent assay kit has the advantages of good specificity, high sensitivity, good accuracy and high stability when being used for detecting the plasticizer in the edible oil; therefore, the enzyme linked immunosorbent assay kit has a good application prospect in the detection of the plasticizer in the edible oil.

Described herein are systems and methods for analyzing cells, including a method comprising: (a) forming a compartment within a fluid, wherein the fluid comprises a plurality of cells, wherein the compartment encloses a cell of the plurality of cells, and wherein the compartment physically separates the cell from an additional cell of the plurality of cells; (b) incubating the cell for about 1 minute to about 10 hours, wherein the cell is inside of the compartment during the incubating; and (c) performing an assay within the compartment, thereby analyzing the cell.

A diagnostic test device to perform a test on a biological or environmental sample is provided. In one aspect, the diagnostic test device includes a chamber configured to receive a fluid from a sample preparation reservoir at a first section of the chamber, and one or more capillary grooves along an inner surface of the chamber. The capillary grooves are configured to promote flow of the fluid toward a second section of the chamber. Embodiments of the diagnostic test reservoir can increase an amount of sample available to an assay reaction, which in one example embodiment occurs within a volume of fluid in the second section of the chamber.

The invention discloses a chemiluminescence heparin binding protein kit and a determination method thereof. The kit comprises reagent components of a reagent R1, a reagent R2 and a reagent R3, as well as a matched calibrator, a matched quality control product, a matched pre-excitation liquid, a matched excitation liquid and a matched cleaning liquid, wherein the reagent R1 contains magnetic particles coated with streptavidin, and the reagent R2 and the reagent R3 are respectively monoclonal antibodies which are labeled by acridinium ester and biotin and are used for recognizing different epitopes of human HBP. The kit shows better sensitivity, wider detection range and high specificity, and can effectively reduce potential endogenous and exogenous interference in clinical samples of potential interference people.

The invention relates to the technical field of industrial process control and data analysis, in particular to a polyacrylamide production process monitoring data analysis system based on reinforcement learning, which comprises a data acquisition step: acquiring process data at a first frequency, and receiving quality data at a second frequency; a strategy generation step: outputting an action by using a neural network, and calculating an instant agency reward by using an agency model; an asynchronous experience playback step: constructing a nonlinear storage structure, and mapping lagging quality data back to historical process data fragments to complete a causal closed loop; a model updating step: calculating a delay correction reward, and updating network parameters based on the mixed reward; according to the invention, decoupling of real-time decision and delay calibration is realized through a dual-time scale architecture, and the response capability and high-precision control of a test vacuum period are ensured.

The present invention pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, and monitoring therapy can be used for prognostic (predictive) purposes to thereby treat an individual having cancer. Accordingly, one aspect of the present invention relates to methods of treating a subject having cancer by determining the amount and / or activity level of ZNFX1 in the context of a biological sample (e.g., blood, serum, cells, or tissue) to thereby determine whether an individual afflicted with a cancer is likely to respond to anti-cancer therapy, whether in an original or recurrent cancer.